

# Acylimines of hexafluoroacetone in cyclocondensation with C,N-binucleophiles

V. B. Sokolov,\* A. Yu. Aksinenko, and I. V. Martynov

Institute of Physiologically Active Compounds, Russian Academy of Sciences,  
142432 Chernogolovka, Moscow Region, Russian Federation.  
Fax: +7(495) 785 7024. E-mail: alaks@ipac.ac.ru

The reactions of acylimines of hexafluoroacetone with 1,3-C,N-binucleophiles giving rise to fluorine-containing 1,4-dihydropyrimidines, including fused compounds, were studied.


**Key words:** acylimines, hexafluoroacetone, 2-aminocrotononitrile, *N*-substituted 3-amino-cyclohexenones, 6-aminouracils, 6-aminothiouracils, 1,4-dihydropyrimidines, 4,6,7,8-tetrahydroquinazolin-5-ones, cyclocondensation, cyclization, bromination.

Acylimines of hexafluoroacetone serve as synthons for the synthesis of various heterocyclic compounds containing geminal trifluoromethyl groups and are used as heterodienes and dienophiles in cycloaddition with nitriles,<sup>1,2</sup> derivatives of trivalent phosphorus acids,<sup>3</sup> and cyclopentadiene<sup>4</sup> as well as 1,3-bielectrophilic reagents in cyclocondensation with 1,3-binucleophiles<sup>5,6</sup> to give oxadiazines, oxazaphospholenes, azanorbornenes, and dihydrotriazines, respectively. In the present study, we examined the synthetic possibilities of acylimines of hexafluoroacetone **1** as 1,3-bielectrophilic reagents for the preparation of 1,4-dihydropyrimidines by cyclocondensation with 1,3-C,N-binucleophiles. It should be noted that 1,4-dihydropyrimidines, including fluorine-containing derivatives, belong to a promising class of biologically active compounds. Some representatives of this class are  $\alpha_1$ -adrenoreceptor antagonists,<sup>7</sup> cytostatics, and compounds having the anti-HIV activity.<sup>8</sup>

The reactions of acylimines with 1,3-C,N-binucleophiles, *viz.*, 2-aminocrotononitrile, 6-aminouracils, 6-aminothiouracils, and *N*-substituted 3-aminocyclohexenones, involve the following two steps (Scheme 1): the addition of a binucleophile at the C=N bond of imine **1** followed by cyclization with water elimination. In the case of 2-aminocrotononitrile **2**, we isolated and identified the addition product, *viz.*, the corresponding benzamide **3**. Heating of the latter in DMF in the presence of catalytic amounts of Et<sub>3</sub>N afforded 1,4-dihydropyrimidine **4a**.

Cyclocondensation of imines **1a–k** with 2-aminocrotononitrile **2**, 6-aminouracils **5a–d**, 6-aminothiouracils **6a,b**, and *N*-substituted 3-aminocyclohexenones **7a–c** (equimolar amounts of the reagents were mixed in DMF at 20 °C and, after completion of the exothermic reaction, the mixture was heated in the presence of catalytic amounts of Et<sub>3</sub>N at 90–100 °C for 5 h


Scheme 1




without isolation of intermediate addition products) afforded 1,4-dihydropyrimidines **4a–f**, dihydropyrimido[4,5-*d*]pyrimidine-2,4-diones **8a–g**, 2-thioxotetrahydropyrimido[4,5-*d*]pyrimidin-4-ones **9a,b**, and tetrahydro-1*H*-quinazolin-5-ones **10a–d** (Scheme 2).

Compounds **4** and **8–10** were prepared in the crystalline state in 67–85% yields. Their compositions and structures were confirmed by elemental analysis and NMR spectroscopy. The <sup>19</sup>F NMR spectra show characteristic signals of the geminal trifluoromethyl groups at  $\delta$  2–6.

Like *N*-allylthioureas,<sup>9</sup> pyrimido[4,5-*d*]pyrimidine-4-diones **9a,b** containing the *N*-allylthioamide fragment are

**Scheme 2**

- 1:** R = Ph (**a**), Me (**b**), Et (**c**), 3-MeC<sub>6</sub>H<sub>4</sub> (**d**), 4-MeOC<sub>6</sub>H<sub>4</sub> (**e**), 3-ClC<sub>6</sub>H<sub>4</sub> (**f**), 4-ClC<sub>6</sub>H<sub>4</sub> (**g**), 2-FC<sub>6</sub>H<sub>4</sub> (**h**), 3-FC<sub>6</sub>H<sub>4</sub> (**i**), 4-FC<sub>6</sub>H<sub>4</sub> (**j**), 3-pyridyl (**k**);  
**2:** R = Ph (**a**), Me (**b**), 3-MeC<sub>6</sub>H<sub>4</sub> (**c**), 4-MeOC<sub>6</sub>H<sub>4</sub> (**d**), 3-ClC<sub>6</sub>H<sub>4</sub> (**e**), 2-FC<sub>6</sub>H<sub>4</sub> (**f**);  
**5:** R' = Ph (**a**), 4-ClC<sub>6</sub>H<sub>4</sub> (**b**), 2-FC<sub>6</sub>H<sub>4</sub> (**c**), 4-FC<sub>6</sub>H<sub>4</sub> (**d**);  
**6, 9:** R' = All (**a**), methylallyl (**b**);  
**7:** R' = PhCH<sub>2</sub> (**a**), 2-C<sub>5</sub>H<sub>4</sub>NCH<sub>2</sub> (**b**), 3-C<sub>5</sub>H<sub>4</sub>NCH<sub>2</sub> (**c**);  
**8:** R = Me, R' = 4-FC<sub>6</sub>H<sub>4</sub> (**a**); R = 2-FC<sub>6</sub>H<sub>4</sub>, R' = 4-ClC<sub>6</sub>H<sub>4</sub> (**b**); R = 3-FC<sub>6</sub>H<sub>4</sub>, R' = 4-FC<sub>6</sub>H<sub>4</sub> (**c**); R = 4-FC<sub>6</sub>H<sub>4</sub>, R' = 2-FC<sub>6</sub>H<sub>4</sub> (**d**); R = 4-FC<sub>6</sub>H<sub>4</sub>, R' = 4-ClC<sub>6</sub>H<sub>4</sub> (**e**); R = 4-ClC<sub>6</sub>H<sub>4</sub>, R' = Ph (**f**); R = 4-ClC<sub>6</sub>H<sub>4</sub>, R' = 2-FC<sub>6</sub>H<sub>4</sub> (**g**);  
**10:** R = Me, R' = 2-C<sub>5</sub>H<sub>4</sub>NCH<sub>2</sub> (**a**); R = Me, R' = 3-C<sub>5</sub>H<sub>4</sub>NCH<sub>2</sub> (**b**); R = Et, R' = PhCH<sub>2</sub> (**c**); R = 3-C<sub>5</sub>H<sub>4</sub>NCH<sub>2</sub>, R' = PhCH<sub>2</sub> (**d**)

**Scheme 3**

- 11:** R = H (**a**), Me (**b**)

brominated to form thiatetraazacyclopenta[*a*]naphthalenes **11a,b** (Scheme 3).

Therefore, acylimines of hexafluoroacetone can be successfully used as 1,3-bielectrophiles in the synthesis of various previously unknown 4,4-bis(trifluoromethyl)-1,4-dihydropyrimidines, including fused derivatives. The ease of the preparation of the latter is determined primarily by the ease of the preparation of 1,3-C,N-binucleophiles, the available procedures for the synthesis of acylimines of hexafluoroacetone,<sup>1,10</sup> and the experimental simplicity of the developed method.

**Table 1.** Yields, melting points, and elemental analysis data for compounds **4a–f**, **8a–g**, **9a,b**, and **10a–d**

Compound	Yield (%)	M.p. /°C	Found Calculated (%)			Molecular formula
			C	H	N	
<b>4a</b>	72	197–199	50.61 50.46	2.87 2.72	12.75 12.61	C <sub>14</sub> H <sub>9</sub> F <sub>6</sub> N <sub>3</sub>
<b>4b</b>	76	176–178	39.69 39.86	2.44 2.60	15.66 15.50	C <sub>9</sub> H <sub>7</sub> F <sub>6</sub> N
<b>4c</b>	81	192–194	51.73 51.88	3.05 3.19	12.27 12.10	C <sub>15</sub> H <sub>11</sub> F <sub>6</sub> N <sub>3</sub>
<b>4d</b>	79	152–154	49.73 49.60	3.19 3.05	11.42 11.57	C <sub>15</sub> H <sub>11</sub> F <sub>6</sub> N <sub>3</sub> O
<b>4e</b>	85	187–189	45.58 45.73	2.04 2.19	11.28 11.43	C <sub>14</sub> H <sub>8</sub> ClF <sub>6</sub> N <sub>3</sub>
<b>4f</b>	69	131–133	48.74 47.88	2.46 2.30	11.81 11.96	C <sub>14</sub> H <sub>8</sub> F <sub>7</sub> N <sub>3</sub>
<b>8a</b>	75	296–298	43.76 43.92	2.07 2.21	13.51 13.66	C <sub>15</sub> H <sub>9</sub> F <sub>7</sub> N <sub>4</sub> O <sub>2</sub>
<b>8b</b>	77	259–261	47.54 47.40	2.11 1.99	11.22 11.06	C <sub>20</sub> H <sub>10</sub> ClF <sub>7</sub> N <sub>4</sub> O <sub>2</sub>
<b>8c</b>	76	311–313	50.15 48.99	2.21 2.06	11.28 11.43	C <sub>20</sub> H <sub>10</sub> F <sub>8</sub> N <sub>4</sub> O <sub>2</sub>
<b>8d</b>	68	308–310	48.84 48.99	1.91 2.06	11.28 11.43	C <sub>20</sub> H <sub>10</sub> F <sub>8</sub> N <sub>4</sub> O <sub>2</sub>
<b>8e</b>	83	311–313	47.24 47.40	2.13 1.99	11.22 11.06	C <sub>20</sub> H <sub>10</sub> ClF <sub>7</sub> N <sub>4</sub> O <sub>2</sub>
<b>8f</b>	78	281–283	49.01 49.15	2.43 2.27	11.31 11.46	C <sub>20</sub> H <sub>11</sub> ClF <sub>6</sub> N <sub>4</sub> O <sub>2</sub>
<b>8g</b>	77	292–294	47.53 47.40	2.14 1.99	11.19 11.06	C <sub>20</sub> H <sub>10</sub> ClF <sub>7</sub> N <sub>4</sub> O <sub>2</sub>
<b>9a</b>	76	211–213	47.15 47.01	2.63 2.78	12.77 12.90	C <sub>17</sub> H <sub>12</sub> F <sub>6</sub> N <sub>4</sub> OS
<b>9b</b>	79	196–197	48.09 48.22	2.31 3.15	12.34 12.50	C <sub>18</sub> H <sub>14</sub> F <sub>6</sub> N <sub>4</sub> OS
<b>10a</b>	82	134–136	54.27 54.42	4.41 4.57	10.19 10.02	C <sub>19</sub> H <sub>19</sub> F <sub>6</sub> N <sub>3</sub> O
<b>10b</b>	78	157–159	54.26 54.42	4.71 4.57	10.13 10.02	C <sub>19</sub> H <sub>19</sub> F <sub>6</sub> N <sub>3</sub> O
<b>10c</b>	74	182–183	58.16 58.33	5.29 5.13	6.32 6.48	C <sub>21</sub> H <sub>22</sub> F <sub>6</sub> N <sub>2</sub> O
<b>10d</b>	79	201–203	59.71 59.88	4.56 4.40	8.84 8.73	C <sub>24</sub> H <sub>21</sub> F <sub>6</sub> N <sub>3</sub> O

## Experimental

The  $^1\text{H}$  and  $^{19}\text{F}$  NMR spectra were recorded on a Bruker DXP 200 spectrometer in  $\text{DMSO-d}_6$ . The melting points were determined in a glass capillary. Acylimines of hexafluoroacetone **1a–k**,<sup>10</sup> the starting 6-aminouracils, 6-aminothiouracils,<sup>11</sup> and 3-aminocyclohexenones<sup>12</sup> were synthesized according to procedures described earlier. Methyl ether and 2-aminocrotononitrile (Aldrich) were used without preliminary purification.

**N-[3-Amino-2-cyano-1,1-bis(trifluoromethyl)but-2-enyl]benzamide (3).** 2-Aminocrotononitrile **2** (0.82 g, 0.01 mol) was added to a solution of imine **1a** (2.69 g, 0.01 mol) in benzene (20 mL). After completion of the exothermic reaction, the benzene was evaporated and the residue was recrystallized from a 1 : 1 benzene–hexane mixture. Benzamide **3** was obtained in a yield of 3.2 g (91.1%), m.p. 161–162 °C. Found (%): C, 47.71; H, 3.03; N, 1.79.  $\text{C}_{14}\text{H}_{11}\text{F}_6\text{N}_3\text{O}$ . Calculated (%): C, 47.87;

H, 3.16; N, 11.96.  $^1\text{H}$  NMR,  $\delta$ : 2.17 (s, 3 H, Me); 6.59 (br.s, 2 H,  $\text{NH}_2$ ); 7.51 (m, 3 H,  $\text{CH}_{\text{Ar}}$ ); 7.89 (d, 2 H,  $\text{CH}_{\text{Ar}}$ ,  $J$  = 6.7 Hz); 8.62 (s, 1 H, NH).  $^{19}\text{F}$  NMR,  $\delta$ : 9.17 (s).

**6-Methyl-2-phenyl-4,4-bis(trifluoromethyl)-1,4-dihydro-pyrimidine-5-carbonitrile (4a).** *A.* A solution of benzamide **3** (1.75 g, 0.005 mol) and  $\text{Et}_3\text{N}$  (0.2 mL) in DMF (10 mL) was heated at 90–100 °C for 5 h. Then the reaction mixture was cooled and poured into water (50 mL). The precipitate that formed was recrystallized from 50% EtOH and compound **4a** was obtained in a yield of 1.2 g (72%), m.p. 197–199 °C.

*B.* A solution of benzoylimine **1** (2.69 g, 0.01 mol) and 2-aminocrotononitrile **2** (0.82 g, 0.01 mol) in DMF (10 mL) was stirred at 20 °C for 1 h. Then  $\text{Et}_3\text{N}$  (0.2 mL) was added. The reaction mixture was heated at 90–100 °C for 5 h, cooled, and poured into water (50 mL). The precipitate that formed was filtered off and recrystallized from 50% EtOH. Compound **4a** was obtained in a yield of 2.7 g (81%), m.p. 197–199 °C.

**Table 2.**  $^1\text{H}$  and  $^{19}\text{F}$  NMR spectra of compounds **4a–f**, **8a–g**, **9a,b**, and **10a–d** in  $\text{DMSO-d}_6$

Com- ound	$\delta$ (J/Hz)	
	$^1\text{H}$	$^{19}\text{F}$
<b>4a</b>	2.38 (s, 3 H, Me); 7.53 (m, 3 H, $\text{CH}_{\text{Ar}}$ ); 7.93 (d, 2 H, $\text{CH}_{\text{Ar}}$ , $J$ = 7.1); 10.86 (s, 1 H, NH)	2.68 (s)
<b>4b</b>	2.04, 2.17 (both s, 3 H each, Me); 9.81 (br.s, 1 H, NH)	2.52 (s)
<b>4c</b>	2.32, 2.45 (both s, 3 H each, Me); 7.33, 7.68 (both m, 2 H each, $\text{CH}_{\text{Ar}}$ ); 10.81 (s, 1 H, NH)	2.73 (s)
<b>4d</b>	2.11 (s, 3 H, Me); 3.87 (s, 3 H, MeO); 6.89, 7.84 (both d, 2 H each, $\text{CH}_{\text{Ar}}$ , $J$ = 8.0); 8.40 (s, 1 H, NH)	3.59 (s)
<b>4e</b>	2.34 (s, 3 H, Me); 7.47, 7.89 (both m, 2 H each, $\text{CH}_{\text{Ar}}$ ); 10.91 (s, 1 H, NH)	3.12 (s)
<b>4f</b>	2.29 (s, 3 H, Me); 7.24, 7.55 (both m, 2 H each, $\text{CH}_{\text{Ar}}$ ); 10.98 (s, 1 H, NH)	3.10 (s, 6 F); −34.86 (m, 1 F)
<b>8a</b>	2.02 (s, 3 H, Me); 7.08 (m, 4 H, $\text{CH}_{\text{Ar}}$ ); 9.73, 11.27 (both s, 1 H each, NH)	4.82 (s, 6 F); −29.05 (m, 1 F)
<b>8b</b>	7.12–7.23 (m, 5 H, $\text{CH}_{\text{Ar}}$ ); 7.43 (d, 2 H, $\text{CH}_{\text{Ar}}$ , $J$ = 8.8); 7.53 (m, 1 H, $\text{CH}_{\text{Ar}}$ ); 9.81, 11.46 (both s, 1 H each, NH)	5.06 (s, 6 F); −34.56 (m, 1 F)
<b>8c</b>	7.19 (m, 5 H, $\text{CH}_{\text{Ar}}$ ); 7.42 (m, 2 H, $\text{CH}_{\text{Ar}}$ ); 7.39 (m, 1 H, $\text{CH}_{\text{Ar}}$ ); 9.55, 11.39 (both s, 1 H each, NH)	5.48 (s, 6 F); −34.64, −35.45 (both m, 1 F each)
<b>8d</b>	7.09 (m, 2 H, $\text{CH}_{\text{Ar}}$ ); 7.29 (m, 3 H, $\text{CH}_{\text{Ar}}$ ); 7.48 (m, 2 H, $\text{CH}_{\text{Ar}}$ ); 7.71 (m, 1 H, $\text{CH}_{\text{Ar}}$ ); 9.60, 11.48 (both s, 1 H each, NH)	5.16 (s, 6 F); −28.14, −42.79 (both m, 1 F each)
<b>8e</b>	7.04 (m, 2 H, $\text{CH}_{\text{Ar}}$ ); 7.23, 7.42 (both d, 2 H each, $\text{CH}_{\text{Ar}}$ , $J$ = 7.7); 7.63 (m, 2 H, $\text{CH}_{\text{Ar}}$ ); 9.55, 11.34 (both s, 1 H each, NH)	5.46 (s, 6 F); −28.43 (m, 1 F)
<b>8f</b>	7.21 (m, 2 H, $\text{CH}_{\text{Ar}}$ ); 7.36 (d, 2 H, $\text{CH}_{\text{Ar}}$ , $J$ = 7.7); 7.47 (m, 3 H, $\text{CH}_{\text{Ar}}$ ); 7.63 (d, 2 H, $\text{CH}_{\text{Ar}}$ , $J$ = 7.7); 9.58, 11.38 (both s, 1 H each, NH)	5.44 (s)
<b>8g</b>	7.24 (m, 4 H, $\text{CH}_{\text{Ar}}$ ); 7.46, 7.73 (both m, 2 H each, $\text{CH}_{\text{Ar}}$ ); 9.71, 11.48 (both s, 1 H each, NH)	5.30 (s, 6 F); −43.04 (m, 1 F)
<b>9a</b>	5.21 (m, 2 H, $\text{CH}_2\text{N}$ ); 5.36 (m, 2 H, $\text{CH}_2=$ ); 5.96 (m, 1 H, $\text{CH}=$ ); 7.55 (m, 3 H, $\text{CH}_{\text{Ar}}$ ); 7.94 (d, 2 H, $\text{CH}_{\text{Ar}}$ , $J$ = 7.9); 9.99, 12.44 (both s, 1 H each, NH)	5.43 (s)
<b>9b</b>	1.93 (s, 3 H, Me); 4.51, 4.81 (both s, 1 H each, $\text{CH}_2\text{N}$ ); 5.24 (s, 2 H, $\text{CH}_2=$ ); 7.47–7.64 (m, 3 H, $\text{CH}_{\text{Ar}}$ ); 7.87 (d, 2 H, $\text{CH}_{\text{Ar}}$ , $J$ = 6.8); 10.02, 12.60 (both s, 1 H each, NH)	5.44 (s)
<b>10a</b>	1.01 (s, 6 H, Me); 2.22 (s, 2 H, $\text{CH}_2$ ); 2.26 (s, 3 H, Me); 2.56, 5.09 (both s, 2 H each, $\text{CH}_2$ ); 7.28 (m, 2 H, $\text{CH}_{\text{Ar}}$ ); 7.78 (t, 1 H, $\text{CH}_{\text{Ar}}$ , $J$ = 7.6); 8.54 (d, 1 H, $\text{CH}_{\text{Ar}}$ , $J$ = 7.6)	6.39 (s)
<b>10b</b>	1.02 (s, 6 H, Me); 2.25 (s, 2 H, $\text{CH}_2$ ); 2.28 (s, 3 H, Me), 2.56, 5.11 (both s, 2 H each, $\text{CH}_2$ ); 7.35, 7.48 (both m, 1 H each, $\text{CH}_{\text{Ar}}$ ); 8.44 (s, 1 H, $\text{CH}_{\text{Ar}}$ ), 8.55 (d, 1 H, $\text{CH}_{\text{Ar}}$ , $J$ = 7.5)	6.10 (s)
<b>10c</b>	0.94 (s, 6 H, Me); 1.12 (t, 3 H, Me, $J$ = 7.5); 2.18 (s, 2 H, $\text{CH}_2$ ); 2.52–2.61 (m, 4 H, $\text{CH}_2 + \text{CH}_2$ ); 4.97 (s, 2 H, $\text{CH}_2$ ); 7.23 (d, 2 H, $\text{CH}_{\text{Ar}}$ , $J$ = 8); 7.27–7.32 (m, 3 H, $\text{CH}_{\text{Ar}}$ )	5.97 (s)
<b>10d</b>	0.97, 1.03 (both s, 3 H each, Me); 2.17 (AB system, 2 H, $\text{CH}_2$ , $J$ = 11.4); 2.48 (m, 2 H, $\text{CH}_2$ ); 4.87 (s, 2 H, $\text{CH}_2$ ); 7.23–7.41 (m, 6 H, $\text{CH}_{\text{Ar}}$ ); 8.22 (d, 1 H, $\text{CH}_{\text{Ar}}$ , $J$ = 7.8); 6.67 (m, 2 H, $\text{CH}_{\text{Ar}}$ )	5.03 (s)

**2,6-Dimethyl-4,4-bis(trifluoromethyl)-1,4-dihydropyrimidine-5-carbonitrile (4b), 6-methyl-2-(3-tolyl)-4,4-bis(trifluoromethyl)-1,4-dihydropyrimidine-5-carbonitrile (4c), 2-(4-methoxyphenyl)-6-methyl-4,4-bis(trifluoromethyl)-1,4-dihydropyrimidine-5-carbonitrile (4d), 2-(3-chlorophenyl)-6-methyl-4,4-bis(trifluoromethyl)-1,4-dihydropyrimidine-5-carbonitrile (4e), 2-(2-fluorophenyl)-6-methyl-4,4-bis(trifluoromethyl)-1,4-dihydropyrimidine-5-carbonitrile (4f), 1-(4-fluorophenyl)-7-methyl-5,5-bis(trifluoromethyl)-5,8-dihydropyrimido[4,5-*d*]pyrimidine-2,4(1*H*,3*H*)-dione (8a), 1-(4-chlorophenyl)-7-(2-fluorophenyl)-5-bis(trifluoromethyl)-5,8-dihydropyrimido[4,5-*d*]pyrimidine-2,4(1*H*,3*H*)-dione (8b), 7-(3-fluorophenyl)-1-(4-fluorophenyl)-5,5-bis(trifluoromethyl)-5,8-dihydropyrimido[4,5-*d*]pyrimidine-2,4(1*H*,3*H*)-dione (8c), 1-(2-fluorophenyl)-7-(4-fluorophenyl)-5,5-bis(trifluoromethyl)-5,8-dihydropyrimido[4,5-*d*]pyrimidine-2,4(1*H*,3*H*)-dione (8d), 1-(4-chlorophenyl)-7-(4-fluorophenyl)-5,5-bis(trifluoromethyl)-5,8-dihydropyrimido[4,5-*d*]pyrimidine-2,4(1*H*,3*H*)-dione (8e), 7-(4-chlorophenyl)-1-phenyl-5,5-bis(trifluoromethyl)-5,8-dihydropyrimido[4,5-*d*]pyrimidine-2,4(1*H*,3*H*)-dione (8f), 7-(4-chlorophenyl)-1-(2-fluorophenyl)-5,5-bis(trifluoromethyl)-5,8-dihydropyrimido[4,5-*d*]pyrimidine-2,4(1*H*,3*H*)-dione (8g), 1-allyl-7-phenyl-2-thioxo-5,5-bis(trifluoromethyl)-2,3,5,8-tetrahydro-1*H*-pyrimido[4,5-*d*]pyrimidin-4-one (9a), 1-(2-methylallyl-2-thioxo)-5,5-bis(trifluoromethyl)-7-phenyl-2,3,5,8-tetrahydro-1*H*-pyrimido[4,5-*d*]pyrimidin-4-one (9b), 2,7,7-trimethyl-1-(pyridin-2-ylmethyl)-4,4-bis(trifluoromethyl)-4,6,7,8-tetrahydro-1*H*-quinazolin-5-one (10a), 2,7,7-trimethyl-1-(pyridin-3-ylmethyl)-4,4-bis(trifluoromethyl)-4,6,7,8-tetrahydro-1*H*-quinazolin-5-one (10b), 1-benzyl-2-ethyl-7,7-dimethyl-4,4-bis(trifluoromethyl)-4,6,7-tetrahydro-1*H*-quinazolin-5-one (10c), and 1-benzyl-7,7-dimethyl-2-(pyridin-3-yl)-4,4-bis(trifluoromethyl)-4,6,7,8-tetrahydro-1*H*-quinazolin-5-one (10d) were prepared analogously to pyrimidinone 4a from acylimines 1a–k (0.01 mol) and the corresponding binucleophiles 5a–d, 6a,b, and 7a,c (0.01 mol). The yields, the melting points, and the spectroscopic characteristics of compounds 4a–f, 8a–g, 9a,b, and 10a–d are given in Tables 1 and 2.**

**2-Bromomethyl-8-phenyl-6,6-bis(trifluoromethyl)-1,2,6,9-tetrahydro-3-thia-4,7,9,9b-tetraazacyclopenta[*a*]naphthalen-5-one (11a).** Bromine (0.8 g, 0.005 mol) was added to a suspension of pyrimidinone 9a (2.17 g, 0.005 mol) in EtOH (20 mL) at 20 °C. The reaction mixture was stirred for 1 h, diluted with H<sub>2</sub>O (50 mL), and neutralized with a 10% NaOH solution. The precipitate that formed was filtered off and recrystallized from 50% EtOH. Compound 11a was obtained in a yield of 2.1 g (82%), m.p. 144–146 °C. Found (%): C, 38.62; H, 2.33; N, 10.77. C<sub>17</sub>H<sub>11</sub>BrF<sub>6</sub>N<sub>4</sub>OS. Calculated (%): C, 39.78; H, 2.16; N, 10.92. <sup>1</sup>H NMR, δ: 3.69 (m, 2 H, CH<sub>2</sub>Br); 4.37 (m, 1 H, CHS); 4.49 and 4.71 (both m, 1 H each, CH<sub>2</sub>N); 7.61 (m, 3 H, CH<sub>Ar</sub>); 7.94 (m, 2 H, CH<sub>Ar</sub>); 9.67 (s, 1 H, NH). <sup>19</sup>F NMR, δ: 5.95 (s).

**2-Bromomethyl-2-methyl-8-phenyl-6,6-bis(trifluoromethyl)-1,2,6,9-tetrahydro-3-thia-4,7,9,9b-tetraazacyclopenta[*a*]naphthalen-5-one (11b)** was prepared analogously to 11a from compound 9b (2.24 g) in a yield of 2.2 g (83%), m.p.

151–153 °C. Found (%): C, 41.17; H, 2.37; N, 10.47, C<sub>18</sub>H<sub>13</sub>BrF<sub>6</sub>N<sub>4</sub>OS. Calculated (%): C, 41.00; H, 2.49; N, 10.63. <sup>1</sup>H NMR, δ: 1.82 (s, 3 H, Me); 4.02 (AB system, 2 H, CH<sub>2</sub>, *J* = 10.4 Hz); 4.24 and 4.80 (both d, 1 H each, CH<sub>2</sub>Br, *J* = 12.5 Hz); 7.55 (m, 3 H, CH<sub>Ar</sub>); 7.93 (d, 2 H, CH<sub>Ar</sub>, *J* = 8.0 Hz); 9.72 (s, 1 H, NH). <sup>19</sup>F NMR, δ: 5.76 (s).

This study was financially supported by the Division of Chemistry and Materials Science of the Russian Academy of Sciences (Program No. 10 of Basic Research "Biomolecular and Medicinal Chemistry").

## References

- S. N. Osipov, A. F. Kolomiets, and A. V. Fokin, *Usp. Khim.*, 1992, **61**, 1457 [*Russ. Chem. Rev.*, 1992, **61** (Engl. Transl.)].
- V. B. Sokolov and A. Yu. Aksinenko, *Izv. Akad. Nauk, Ser. Khim.*, 1998, 748 [*Russ. Chem. Bull.*, 1998, **47**, 727 (Engl. Transl.)].
- O. V. Korenchenko, A. Yu. Aksinenko, V. B. Sokolov, and I. V. Martynov, *Heteroatom Chem.*, 1992, **3**, 147.
- O. V. Korenchenko, A. Yu. Aksinenko, V. B. Sokolov, A. N. Pushin, and I. V. Martynov, *Izv. Akad. Nauk, Ser. Khim.*, 1995, 1809 [*Russ. Chem. Bull.*, 1995, **44**, 1740 (Engl. Transl.)].
- V. B. Sokolov, A. Yu. Aksinenko, T. A. Epishina, T. V. Goreva, and I. V. Martynov, *Izv. Akad. Nauk, Ser. Khim.*, 2005, 462 [*Russ. Chem. Bull., Int. Ed.*, 2005, **54**, 472].
- V. B. Sokolov and A. Yu. Aksinenko, *Izv. Akad. Nauk, Ser. Khim.*, 2005, 1470 [*Russ. Chem. Bull., Int. Ed.*, 2005, **54**, 1514].
- W. C. Wong, W. Sun, B. Lagu, D. Tian, M. R. Marzabadi, F. Zhang, D. Nagarathnam, S. W. Miao, J. M. Wetzel, J. Peng, C. Forray, R. S. L. Chang, T. B. Chen, R. Ransom, S. O'Malley, T. P. Broten, P. Kling, K. P. Vyas, K. Zhang, and C. Gluchowski, *J. Med. Chem.*, 1999, **42**, 4804.
- A. Mai, M. Artico, G. Sbardella, S. Massa, E. Novellino, G. Greco, A. G. Loi, E. Tramontano, M. E. Marongiu, and P. La Colla, *J. Med. Chem.*, 1999, **42**, 619.
- V. M. Fedoseev and Yu. M. Evdokimov, *Zh. Obshch. Khim.*, 1964, **34**, 1551 [*J. Gen. Chem. USSR*, 1964, **34** (Engl. Transl.)].
- O. V. Korenchenko, V. B. Sokolov, A. Yu. Aksinenko, and I. V. Martynov, *Izv. Akad. Nauk SSSR, Ser. Khim.*, 1990, 373 [*Bull. Acad. Sci. USSR, Div. Chem. Sci.*, 1990, **39**, 313 (Engl. Transl.)].
- W. Hutzenlaub and W. Pfleiderer, *Lieb. Ann. Chem.*, 1979, 1847.
- I. O. Edafiogho, C. N. Hinko, H. Chang, J. A. Moore, D. Mulzac, J. M. Nicholson, and K. R. Scott, *J. Med. Chem.*, 1992, **35**, 2798.

Received June 16, 2005;  
in revised form November 17, 2005